Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
Evofem Biosciences announced that Favor, a female telehealth provider, has added its hormone-free contraceptive gel, Phexxi, to its product offerings. Favor aims to provide patients with a non-hormonal option alongside over 120 hormonal contraceptives. The collaboration is expected to enhance retail channel growth in 2023. Favor has prescribed contraception to over three million patients since 2016, addressing the increasing demand for non-hormonal birth control methods. This partnership reflects Evofem's commitment to innovative solutions in women's reproductive health.
- Addition of Phexxi to Favor's offerings expands access to non-hormonal contraceptive options.
- Collaboration expected to contribute to retail growth in 2023.
- Favor has a proven track record, having prescribed contraception to over three million patients.
- None.
-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio --
Favor (formerly called
"We are delighted that Favor is expanding its portfolio to offer its patients a non-hormonal contraceptive - Phexxi," said
"We are proud to offer Phexxi for women and people who menstruate seeking non-hormonal contraceptive options," said
About Favor
Favor is a leading digital healthcare platform on a mission to empower women and people who menstruate to lead their healthiest lives. The company combines telemedicine and direct-to-consumer pharmacy with the broadest insurance coverage in the space. Since their founding in 2016, Favor has evolved from a single-point solution focused on birth control delivery and reproductive healthcare to a coordinated care provider that seeks to expand access to affordable, convenient, and accessible healthcare.
About Evofem
Phexxi® is a registered trademark of
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the timing and impact of the collaboration's contribution to retail channel growth. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of
Contacts
SVP, Investor Relations
araskopf@evofem.com / media@evofem.com
(917) 673-5775
Favor
Director of Communications
sarah.abboud@heyfavor.com
740-579-1829
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofems-phexxi-contraceptive-gel-to-be-offered-by-female-telehealth-leader-favor-formerly-the-pill-club-301720027.html
SOURCE
FAQ
What is the significance of Evofem's partnership with Favor?
When did Evofem announce the collaboration with Favor?
What product is being offered by Favor?